Market Overview

Benzinga's Top Upgrades, Downgrades For March 4, 2020

Share:

Upgrades

  • Wedbush changed the rating for AGNC Investment Corp (NASDAQ: AGNC) from Neutral to Outperform. In the fourth quarter, AGNC Investment showed an EPS of $0.57, compared to $0.53 from the year-ago quarter. The stock has a 52-week-high of $19.65 and a 52-week-low of $14.51. AGNC Investment's stock last closed at $17.88 per share.
  • B. Riley FBR upgraded the stock for International Seaways Inc (NYSE: INSW) from Neutral to Buy. International Seaways earned $1.32 in the fourth quarter, compared to $0.32 in the year-ago quarter. The stock has a 52-week-high of $31.39 and a 52-week-low of $15.15. International Seaways's stock last closed at $20.57 per share.
  • For AptarGroup Inc (NYSE: ATR), Wells Fargo upgraded the stock from Equal-Weight to Overweight. For the fourth quarter, AptarGroup had an EPS of $0.80, compared to year-ago quarter EPS of $0.92. The stock has a 52-week-high of $126.19 and a 52-week-low of $99.21. AptarGroup's stock last closed at $102.62 per share.
  • B of A Securities changed the rating for Highwoods Properties Inc (NYSE: HIW) from Neutral to Buy. Highwoods Properties earned $0.91 in the fourth quarter, compared to $0.86 in the year-ago quarter. The stock has a 52-week-high of $52.76 and a 52-week-low of $40.75. Highwoods Properties's stock last closed at $46.60 per share.
  • Janney Capital upgraded the stock for American States Water Co (NYSE: AWR) from Neutral to Buy. American States Water earned $0.45 in the fourth quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $96.00 and a 52-week-low of $67.52. American States Water's stock last closed at $81.07 per share.
  • First Analysis changed the rating for Proofpoint Inc (NASDAQ: PFPT) from Outperform to Strong Buy. Proofpoint earned $0.52 in the fourth quarter, compared to $0.51 in the year-ago quarter. The stock has a 52-week-high of $133.58 and a 52-week-low of $102.25. Proofpoint's stock last closed at $107.40 per share.
  • Nomura changed the rating for The Home Depot Inc (NYSE: HD) from Neutral to Buy. Home Depot earned $2.28 in the fourth quarter, compared to $2.25 in the year-ago quarter. The stock has a 52-week-high of $247.36 and a 52-week-low of $179.52. Home Depot's stock last closed at $227.93 per share.
  • Societe Generale upgraded the stock for Oracle Corp (NYSE: ORCL) from Hold to Buy. For the second quarter, Oracle had an EPS of $0.90, compared to year-ago quarter EPS of $0.80. The stock has a 52-week-high of $60.50 and a 52-week-low of $47.90. Oracle's stock last closed at $48.86 per share.
  • Citigroup changed the rating for Morgan Stanley (NYSE: MS) from Neutral to Buy. Morgan Stanley earned $1.20 in the fourth quarter, compared to $0.73 in the year-ago quarter. The stock has a 52-week-high of $57.57 and a 52-week-low of $38.76. Morgan Stanley's stock last closed at $44.39 per share.
  • JP Morgan changed the rating for Arista Networks Inc (NYSE: ANET) from Underweight to Neutral. For the fourth quarter, Arista Networks had an EPS of $2.29, compared to year-ago quarter EPS of $2.25. The stock has a 52-week-high of $331.27 and a 52-week-low of $173.31. Arista Networks's stock last closed at $191.66 per share.
  • B. Riley upgraded the stock for International Seaways Inc (NYSE: INSW) from Neutral to Buy. In the fourth quarter, International Seaways showed an EPS of $1.32, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $31.39 and a 52-week-low of $15.15. International Seaways's stock last closed at $20.57 per share.
  • For Chipotle Mexican Grill Inc (NYSE: CMG), Wells Fargo upgraded the stock from Equal-Weight to Overweight. In the fourth quarter, Chipotle Mexican Grill showed an EPS of $2.86, compared to $1.72 from the year-ago quarter. The stock has a 52-week-high of $940.28 and a 52-week-low of $604.64. Chipotle Mexican Grill's stock last closed at $735.80 per share.
  • KeyBanc changed the rating for Mattel Inc (NASDAQ: MAT) from Sector Weight to Overweight. In the fourth quarter, Mattel showed an EPS of $0.11, compared to $0.04 from the year-ago quarter. The stock has a 52-week-high of $15.19 and a 52-week-low of $9.06. Mattel's stock last closed at $11.85 per share.

 

Downgrades

  • H.C. Wainwright downgraded the stock for SpringWorks Therapeutics Inc (NASDAQ: SWTX) from Buy to Neutral. For the third quarter, SpringWorks Therapeutics had an EPS of ($1.77), compared to year-ago quarter EPS of ($11.55). The stock has a 52-week-high of $42.66 and a 52-week-low of $17.02. SpringWorks Therapeutics's stock last closed at $41.21 per share.
  • For Unum Therapeutics Inc (NASDAQ: UMRX), Wedbush downgraded the stock from Outperform to Neutral. For the second quarter, Unum Therapeutics had an EPS of ($0.34), compared to year-ago quarter EPS of ($0.31). The stock has a 52-week-high of $4.87 and a 52-week-low of $0.48. Unum Therapeutics's stock last closed at $0.53 per share.
  • For Okta Inc (NASDAQ: OKTA), Needham downgraded the stock from Buy to Hold. Okta earned ($0.07) in the third quarter, compared to ($0.04) in the year-ago quarter. The stock has a 52-week-high of $142.98 and a 52-week-low of $70.44. Okta's stock last closed at $131.34 per share.
  • Compass Point downgraded the stock for Atlantic Union Bankshares Corp (NASDAQ: AUB) from Buy to Neutral. For the fourth quarter, Atlantic Union Bankshares had an EPS of $0.71, compared to year-ago quarter EPS of $0.70. The stock has a 52-week-high of $40.20 and a 52-week-low of $28.95. Atlantic Union Bankshares's stock last closed at $29.01 per share.
  • Compass Point downgraded the stock for Provident Bancorp Inc (NASDAQ: PVBC) from Buy to Neutral. Provident Bancorp earned $0.14 in the fourth quarter, compared to $0.15 in the year-ago quarter. The stock has a 52-week-high of $28.46 and a 52-week-low of $10.75. Provident Bancorp's stock last closed at $10.99 per share.
  • Compass Point downgraded the stock for Independent Bank Corp (NASDAQ: INDB) from Buy to Neutral. In the fourth quarter, Independent Bank showed an EPS of $1.38, compared to $1.29 from the year-ago quarter. The stock has a 52-week-high of $87.64 and a 52-week-low of $62.33. Independent Bank's stock last closed at $69.57 per share.
  • Compass Point changed the rating for First Hawaiian Inc (NASDAQ: FHB) from Buy to Neutral. First Hawaiian earned $0.54 in the fourth quarter, compared to $0.58 in the year-ago quarter. The stock has a 52-week-high of $31.25 and a 52-week-low of $23.52. First Hawaiian's stock last closed at $24.20 per share.
  • Compass Point downgraded the stock for Western New England Bancorp Inc (NASDAQ: WNEB) from Buy to Neutral. The stock has a 52-week-high of $10.15 and a 52-week-low of $8.50. Western New England's stock last closed at $8.60 per share.
  • Barclays downgraded the stock for Nordstrom Inc (NYSE: JWN) from Equal-Weight to Underweight. For the fourth quarter, Nordstrom had an EPS of $1.42, compared to year-ago quarter EPS of $1.48. The stock has a 52-week-high of $48.87 and a 52-week-low of $25.01. Nordstrom's stock last closed at $33.43 per share.
  • For Forty Seven Inc (NASDAQ: FTSV), Mizuho downgraded the stock from Buy to Neutral. Forty Seven earned ($0.38) in the third quarter, compared to ($0.71) in the year-ago quarter. The stock has a 52-week-high of $94.68 and a 52-week-low of $5.53. Forty Seven's stock last closed at $94.24 per share.

 

Initiations

  • With a rating of Outperform, Raymond James initiated coverage on Dynatrace Inc (NYSE: DT). The price target is set at $38.00 for Dynatrace. In the third quarter, Dynatrace earned $0.10. The stock has a 52-week-high of $37.06 and a 52-week-low of $17.05. Dynatrace's stock last closed at $31.49 per share.
  • With a rating of Overweight, Barclays initiated coverage on Epizyme Inc (NASDAQ: EPZM). The price target is set at $33.00 for Epizyme. For the fourth quarter, Epizyme had an EPS of ($0.59), compared to year-ago quarter EPS of ($0.29). The stock has a 52-week-high of $27.82 and a 52-week-low of $9.73. Epizyme's stock last closed at $20.72 per share.
  • Barclays initiated coverage on Xencor Inc (NASDAQ: XNCR) with an Underweight rating. The price target for Xencor is set at $28.00. Xencor earned ($0.47) in the fourth quarter, compared to ($0.32) in the year-ago quarter. The stock has a 52-week-high of $46.33 and a 52-week-low of $27.75. Xencor's stock last closed at $32.59 per share.
  • Barclays initiated coverage on Nektar Therapeutics (NASDAQ: NKTR) with an Overweight rating. The price target for Nektar Therapeutics is set at $30.00. In the fourth quarter, Nektar Therapeutics showed an EPS of ($0.64), compared to ($0.57) from the year-ago quarter. The stock has a 52-week-high of $40.51 and a 52-week-low of $15.63. Nektar Therapeutics's stock last closed at $19.43 per share.
  • With a rating of Overweight, Barclays initiated coverage on Iovance Biotherapeutics Inc (NASDAQ: IOVA). The price target is set at $45.00 for Iovance Biotherapeutics. For the fourth quarter, Iovance Biotherapeutics had an EPS of ($0.50), compared to year-ago quarter EPS of ($0.27). The stock has a 52-week-high of $36.25 and a 52-week-low of $9.21. Iovance Biotherapeutics's stock last closed at $35.79 per share.
  • With a rating of Equal-Weight, Barclays initiated coverage on Agios Pharmaceuticals Inc (NASDAQ: AGIO). The price target is set at $50.00 for Agios Pharmaceuticals. For the fourth quarter, Agios Pharmaceuticals had an EPS of ($1.60), compared to year-ago quarter EPS of ($1.58). The stock has a 52-week-high of $68.94 and a 52-week-low of $28.36. Agios Pharmaceuticals's stock last closed at $46.78 per share.
  • With a rating of Underweight, Barclays initiated coverage on Macrogenics Inc (NASDAQ: MGNX). The price target is set at $8.00 for Macrogenics. Macrogenics earned ($0.62) in the fourth quarter, compared to ($1.06) in the year-ago quarter. The stock has a 52-week-high of $20.95 and a 52-week-low of $7.42. Macrogenics's stock last closed at $8.65 per share.
  • With a rating of Overweight, Barclays initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX). The price target is set at $15.00 for Syndax Pharmaceuticals. For the fourth quarter, Syndax Pharmaceuticals had an EPS of ($0.44), compared to year-ago quarter EPS of ($0.70). The stock has a 52-week-high of $11.33 and a 52-week-low of $4.52. Syndax Pharmaceuticals's stock last closed at $9.27 per share.
  • Barclays initiated coverage on Exelixis Inc (NASDAQ: EXEL) with an Overweight rating. The price target for Exelixis is set at $26.00. Exelixis earned $0.26 in the fourth quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $25.31 and a 52-week-low of $15.02. Exelixis's stock last closed at $18.74 per share.
  • Barclays initiated coverage on Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) with an Overweight rating. The price target for Deciphera Pharmaceuticals is set at $70.00. In the third quarter, Deciphera Pharmaceuticals showed an EPS of ($1.28), compared to ($0.65) from the year-ago quarter. The stock has a 52-week-high of $71.11 and a 52-week-low of $19.88. Deciphera Pharmaceuticals's stock last closed at $56.04 per share.
  • With a rating of Overweight, Barclays initiated coverage on Arcus Biosciences Inc (NYSE: RCUS). The price target is set at $24.00 for Arcus Biosciences. For the third quarter, Arcus Biosciences had an EPS of ($0.51), compared to year-ago quarter EPS of ($0.25). The stock has a 52-week-high of $18.44 and a 52-week-low of $6.30. Arcus Biosciences's stock last closed at $16.65 per share.
  • Barclays initiated coverage on Fate Therapeutics Inc (NASDAQ: FATE) with an Overweight rating. The price target for Fate Therapeutics is set at $40.00. Fate Therapeutics earned ($0.37) in the fourth quarter, compared to ($0.25) in the year-ago quarter. The stock has a 52-week-high of $32.39 and a 52-week-low of $12.59. Fate Therapeutics's stock last closed at $28.25 per share.
  • With a rating of Overweight, Barclays initiated coverage on Karyopharm Therapeutics Inc (NASDAQ: KPTI). The price target is set at $30.00 for Karyopharm Therapeutics. In the fourth quarter, Karyopharm Therapeutics showed an EPS of ($0.76), compared to ($0.96) from the year-ago quarter. The stock has a 52-week-high of $29.61 and a 52-week-low of $3.92. Karyopharm Therapeutics's stock last closed at $24.68 per share.
  • Piper Sandler initiated coverage on Qualcomm Inc (NASDAQ: QCOM) with a Neutral rating. The price target for Qualcomm is set at $80.00. For the first quarter, Qualcomm had an EPS of $0.99, compared to year-ago quarter EPS of $1.20. The stock has a 52-week-high of $96.17 and a 52-week-low of $53.03. Qualcomm's stock last closed at $78.56 per share.
  • Cantor Fitzgerald initiated coverage on ZIOPHARM Oncology Inc (NASDAQ: ZIOP) with an Overweight rating. The price target for ZIOPHARM Oncology is set at $6.00. In the fourth quarter, ZIOPHARM Oncology showed an EPS of ($0.09), compared to ($0.08) from the year-ago quarter. The stock has a 52-week-high of $7.25 and a 52-week-low of $2.68. ZIOPHARM Oncology's stock last closed at $2.90 per share.
 

Related Articles (AGNC + AGIO)

View Comments and Join the Discussion!

Posted-In: Initiations top upgradesUpgrades Downgrades Initiation Intraday Update Analyst Ratings

Latest Ratings

StockFirmActionPT
INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com